Your session is about to expire
← Back to Search
Siplizumab for Sickle Cell Anemia (CD2 SCD Trial)
CD2 SCD Trial Summary
This trial will assess the safety and effectiveness of siplizumab for SCD patients undergoing allogeneic stem cell transplants to reduce GVHD and graft failure.
CD2 SCD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCD2 SCD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CD2 SCD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Am I eligible to be a participant in this research project?
"To qualify for this study, individuals must be afflicted with sickle cell anemia and fall between 18 to 50 years old. Presently, the investigation is searching for a total of 18 participants."
Is the age restriction for this research greater than 25 years old?
"To qualify for the trial, participants must be between 18 and 50 years old. Furthermore, there are 119 trials available to those under 18 and 79 options for seniors over 65."
Are researchers currently seeking out participants for this study?
"Correct, the information on clinicaltrials.gov divulges that this trial is seeking candidates; the trial was first mentioned on September 28th 2023 and has been revised as of October 9th 2023."
How many subjects are enrolled in this experiment?
"Affirmative. Information available on clinicaltrials.gov attests that the study, which was initially posted on 28 September 2023, is currently in search of 18 participants at a single medical site. The trial's data has been most recently updated on 9 October 2023."
Share this study with friends
Copy Link
Messenger